PROF Maarten IJzerman

PROF Maarten IJzerman


  • Cancer Health Services Research (Health Economics, Value-Based Healthcare, Liquid Biopsies, Personalized Medicine, Decision Modelling)



  • Maarten J. IJzerman is a full professor and the VCCC Chair of Cancer Health Services Research in the School of Population and Global Health and the Faculty of Medicine, Dentistry and Health Sciences in Melbourne Australia. He also holds a fractional appointment as a full professor in the University of Twente, the Netherlands. He is leading a global research team working on data-driven value-based cancer care and the role of molecular diagnostic for personalized medicine, in particular cancer and childhood arthritis. He research expertise is health economics, clinical decision support and health services research. Following his PhD in 1997, he was appointed CEO of the Roessingh Rehabilitation Research Institute. In 2007 he was appointed professor and chair in the University of Twente, where he initiated the HTSR department, directed the Health Sciences program (2007-2011), served as the acting director of the MIRA institute for Biomedical Engineering and Technical Medicine (2013-2014) and was the dean for Health & Biomedical Technology in the School of Science and Technology (2015-2017). Maarten is an active global researcher. He developed international research experience at Case Western Reserve University / Metrohealth (Cleveland, USA), Johns Hopkins School of Public Health (Baltimore, USA) and recently the Harvard School of Public Health (Boston, USA). He is an active member of international societies, such as the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), where he was a member of the Board of Directors between 2013-2015, and the program chair for the 20th European meeting (2017) in Glasgow, UK. Maarten is a member of the Board of Directors of a large teaching hospital (Maximá Medisch Centrum) and an institute for radiation oncology (Radiotherapiegroep) in the Netherlands.   


Member of

  • European Society for Medical Oncology (ESMO). Member Working Group Expensive Cancer Medicines 2016 -
  • International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Member Health Sciences Policy Council and different Taskforces 2007 -
  • Health Technology Assessment international. Member 2005 -
  • Society for Medical Decision Making (SMDM). Regular member 2000 -


Selected publications


Investigator on

Additional Grant Information

  • Technology Assessment in Oncology (TANGO) (ZONMW 80-84600-98-1002). 2. UCAN-CANDU: Understanding Childhood Arthritis - Canadian-Dutch (CIHR/ZONMW Application No. 381280). 1-5-2007 / 1-5-2022 3. ELBA: European Liquid Biopsies Academy (EU – ITN H2020 MSCA-ITN-2017 / 765492) 1-12-2017 - 1-12-2021 4. CTC-STOP trial: Health Economics workpackage. Institute for Cancer Research, London UK. 1-6-2017 / 1-6-2022 5. Predictive biomarkers mCRPC: Health Economics. Prostate Cancer UK MA-PM16-002. 1-6-2018 / 1-6-2022 6. B3CARE: Big 3 Screening. 7. CANCER-ID. Innovative Medicines Initiative (IMI).   


Education and training

  • MSc, 2002
  • -, University of York 2000
  • PhD, University of Twente 1997
  • MSc, Radboud Universiteit Nijmegen 1993
  • BSc, Saxion Hogescholen Enschede 1990

Awards and honors

  • Service Award ISPOR for co-chairing Annual European meeting, Glasgow UK, 2017, 2017
  • Taskforce co-chair, Service Award ISPOR for chairing the ISPOR Taskforce on MCDA, 2016
  • Serving on Board of Directors (2013-2015), ISPOR Distinguished Service Award for serving on the Board of Directors, 2015
  • University prize, MSc Thesis Award at the University Medical Center Nijmegen on “functional outcome after trapezio-metacarpal joint arthroplasty in osteoarthritis”, 1994



Available for supervision

  • Y

Supervision Statement

  • I have been an active supervisor for at least 24 PhD students and 75 MSc students over the last 15 years, and currently supervise another 5 PhD students. I am keen on working with young and ambitious researchers, and you can certainly approach me for supervision of projects related to cancer health services research. More specifically, I'd be open for any request in the field of decision analytic modelling and data-science for improving value-based cancer care and the optimal use of diagnostic testing including genomic sequencing.